3M Company (MMM) records an impressive performance in the bio-tech market characterized by
strong operational performance and notable
market gains despite overall market declines. The company’s financial health seems robust, with
annual profit forecasts in the face of sluggish electronics and China's demand. Surpassing Q1 official expectations, 3M also reports inflated
earnings and revenues year-over-year. Following the
spin-off of its Healthcare unit, Solventum, 3M plans for a dividend reduction, which has stirred mixed reactions since the company has a rich tradition of high dividends. However, 3M's
stock remains attractive with an intrinsic evaluation suggesting it is
47% undervalued. The company undertakes strategic moves, such as
appointing Bill Brown as the new CEO and investing in hydrogen electrolyzer manufacturer EVOLOH. On the downside, shareholders have experienced a
45% loss over five years. Nonetheless, the consensus among brokers is to
'Hold' the stock.
3m Company MMM News Analytics from Thu, 16 Nov 2023 08:00:00 GMT to Thu, 16 May 2024 17:49:03 GMT -
Rating 8
- Innovation 6
- Information 7
- Rumor 1
